Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

INDSWFTLAB · NSE

Ind-Swift Laboratories

₹395.15

▲ +1.65%

Close (EOD), as of 1 Oct 2026 · source

Not in active coverage. Cited reporting has mentioned Ind-Swift Laboratories, the record of those mentions is below. Your interest is logged; coverage expands by demand.

Mentions in cited reporting

Bliss GVS Pharma has surged 362% over the past year, while Ind-Swift Laboratories, Sakar Healthcare, Shilpa Medicare and Kwality Pharmaceuticals have jumped 281%, 217%, 149% and 282%, respectively.

ndtvprofit.comsingle-source report23 Sep 2026

Every claim carries its citation

This page lists where cited reporting has mentioned Ind-Swift Laboratories. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.